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ABSTRACT
* 
Self-monitoring of blood glucose (SMBG) is clearly 
correlated with increased life expectancy and quality 
of life in type 2 diabetic patients.  
Objective: The objective of our study was to record 
and assess the errors patients make in preparing, 
performing, and processing self-monitoring of blood 
glucose (SMBG). Furthermore, the study aimed to 
determine to what extent a single standardized 
SMBG instruction session in a community pharmacy 
might reduce the number of patients making errors 
or the number of errors per patient.  
Methods: Between May and October 2005, SMBG 
of 462 randomly selected patients with type 2 
diabetes was monitored in 32 pharmacies 
specialized in diabetes care. The patients 
performed blood glucose self-tests using their own 
blood glucose meters. Self-testing was monitored 
using a standardized documentation sheet on which 
any error made during the performance of the test 
was recorded. If necessary, patients were instructed 
in the accurate operation of their meter and the use 
of the necessary equipment. Additionally, patients 
obtained written instructions. Six weeks later, 
assessment of the quality of patient’s SMBG was 
repeated. 
Results: During the first observation, 383 patients 
(83%) made at least one mistake performing 
SMBG. By the time of the second observation, this 
frequency had fallen to 189 (41%) (p<0.001). The 
average number of mistakes fell from 3.1 to 0.8 per 
patient. Mistakes that may potentially have led to 
inaccurate readings were initially recorded for 283 
(61%) and at study end for 110 (24%) patients 
(p<0.001).  
Conclusion: It is important to periodically instruct 
type 2 diabetic patients in the proper SMBG 
technique in order to ensure accurate 
measurements. In this study it was shown that 
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RESUMEN 
El auto-control de la glucemia está claramente 
correlacionado con un aumento de la esperanza de 
vida y la calidad de vida en diabéticos tipo 2. 
Objetivo: El objetivo de nuestro estudio fue 
registrar y evaluar los errores que cometen los 
pacientes al preparar, ejecutar y procesar el 
autocontrol de glucemia. Además el estudio trató de 
determinar como una formación estandarizada de 
autocontrol de glucemia en una farmacia 
comunitaria podría reducir el número de pacientes 
que cometen errores o el número de errores por 
pacientes. 
Métodos: Entre mayo y octubre de 2005, se 
seleccionaron autocontroles de glucemia de 462 
pacientes con diabetes tipo 2 aleatoriamente 
elegidos en 32 farmacias especializadas en atención 
de diabetes. Los pacientes realizaron autocontroles 
de glucemia usando su propio medidor. El 
autocontrol fue monitorizado utilizando una hoja 
estandarizada de documentación en la que se 
registraba cada error cometido durante la ejecución. 
Si era necesario, se instruía a los pacientes en la 
operativa adecuada de su medidor y en el uso del 
equipo necesario. Además, se entregaban a los 
pacientes instrucciones escritas. Seis semanas 
después, se repetía la evaluación de la calidad del 
autocontrol de glucemia del paciente. 
Resultados: Durante la primera observación, 383 
pacientes (83%) cometieron al menos un error en la 
ejecución. En la segunda observación esta 
frecuencia había caído a 189 (41%) (p<0,001). La 
media de errores calló de 3,1 a 0,8 por paciente. 
Los errores que podían potencialmente llevar a 
lecturas inadecuadas fueron inicialmente en 283 
(61%) y el final del estudio en 110 (24%) de los 
pacientes (p<0,001). 
Conclusión: Es importante instruir periodicamente 
a los diabéticos tipo 2 en el uso correcto de la 
tecnica de autocontrol de la glucemia para asegurar 
mediciones exactas. En este estudio se mostró que 
las farmacias comunitarias especializadas en 
atención de diabetes pueden proporcionar este 
servicio de modo efectivo. 
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INTRODUCTION 
An important goal in the treatment of diabetes is to 
achieve and maintain blood glucose levels as close 
to normal as possible. That is why it is essential to 
train patients in how to effectively self-manage their 
diabetes,
1-5 not only to improve their treatment but 
also to improve their quality of life. The development 
in the late 1970s of methods to self-monitor blood 
glucose levels
6,7 was an indispensable prerequisite 
for this. 
Only through regular self-monitoring of blood 
glucose levels (SMBG) it has become possible to 
coordinate drug therapy as well as food intake and 
exercise so that a good metabolic control can be 
achieved.
8-10 Furthermore, it has become easier to 
identify asymptomatic hypo- and hyperglycemias 
and blood glucose fluctuations.  
According to recommendations of the German 
Diabetes Society (DDG), regular monitoring of blood 
glucose should be conducted by all persons with 
type 1 diabetes after they have undergone specific 
training. The benefit of regular SMBG in this therapy 
concept is evidence-based.
11  
For patients with type 2 diabetes the situation is 
more differentiated. For this group of patients, the 
DDG recommends blood glucose measurements 
when therapeutic consequences result from the 
readings.
12 The benefit of SMBG is not disputed for 
intensified insulin treatment. This is different for 
patients who are treated only with a diabetic 
nutrition plan, with oral antidiabetic drugs (OAD), or 
with conventional insulin treatment. Until now for 
them SMBG was only indicated under certain 
circumstances e.g., for an abnormal renal threshold 
or pregnancy. The benefit of regular blood glucose 
testing for this patient group has been the subject of 
controversial discussion for decades.
8-10,13-18 The 
ROSSO study provided recently clear evidence on 
the benefits of SMBG for type 2 diabetic patients, 
for the first time. For the SMBG group, the risk of 
developing cardiovascular diseases was about one 
third lower than for the group without self-
monitoring, and the mortality rate was even 50% 
lower. Also for the subgroup of patients not 
receiving insulin, the morbidity risk was about a third 
lower and the mortality risk was about 40% lower 
when compared to the control group not performing 
SMBG.
19 The ROSSO study concludes that people 
with type 2 diabetes benefit from SMBG, regardless 
of their kind of treatment. 
The quality of SMBG depends on the quality of the 
blood glucose meter and how well the user 
prepares and carries out the test and performs the 
follow-up steps. 
Most commonly used meters cover the blood 
glucose range of 0.6 – 33.3 mmol/L (10-600 mg/dL). 
For laboratory testing, according to German Medical 
Association guidelines on the quality assurance of 
quantitative tests in medical laboratories, maximal 
deviations of the individual levels of ± 15% are 
allowed.
20 For test strips and sensors for blood 
glucose meters at least 95% of all results must be 
within a ± 20% deviation from the true value.
21 
Due to the progress achieved in recent years in the 
development of new systems for blood glucose self-
monitoring, the meters currently available on the 
market are easy to use. Nevertheless, this user-
friendliness does not ensure that the readings are 
error-free. Different studies on the evaluation of 
blood glucose self-monitoring in individuals with 
diabetes have shown that a number of errors occur 
during the self-monitoring.
22-32 The American 
Diabetes Association (ADA) assumed in a 
consensus report published in 1990 that up to 50% 
of the self-monitored blood glucose readings have 
more than 20% deviation from the true values.
33 
However, more recent studies found the percentage 
of deviation to be less. Alto et al. found deviations of 
over 20% in 16% of the study participants
22 and 
Kabadi et al. found greater deviations in 25% of the 
participants.
24 In the studies of Bergenstal and 
Schrot et al., 19% and 31%, respectively, of the 
readings deviated more than 15% from the control 
reading.
27,30 
To reduce this error rate, the ADA recommends 
regular evaluations of the patients’ SMBG by 
healthcare professionals.
34  
The aims of this study were to determine the quality 
of SMBG performed by individuals with type 2 
diabetes and to reduce the number of patients who 
make errors or the number of errors per patient. 
These were to be accomplished by offering a 
structured training session in self-monitoring in 
community pharmacies. The purpose of the study 
was not to test the accuracy of the readings or to 
validate the blood glucose meters. Taking venous 
blood samples is not allowed in pharmacies in 
Germany, and therefore no exact quality-controlled 
laboratory readings of the blood glucose 
concentrations could be provided. 
 
METHODS  
The study was conducted in the pharmacies 
between May and October 2005.  
The project was designed as a prospective multi-
center intervention study.  
Since several studies have shown that patient 
education tends to increase the quality of 
SMBG
25,26,29,30 we decided to make a before-and-
after comparison. To achieve this, the number of 
patients who made errors in performing the self-
monitoring as well as the average number of errors 
were compared at the beginning of the study and 6 
weeks later. The purpose was to assess whether 
the one-time patient education session in SMBG 
had any effect on how well the patients performed 
the self-monitoring. 
Since this study was not a clinical trial in the sense 
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Medical Devices Act, no approval was needed by 
an ethic committee. Further training courses within 
the framework of the study were not required for the 
participating pharmacies, because on the basis of 
the defined inclusion criteria it could be assumed 
that a high level of counseling competence already 
existed with respect to conducting SMBG. This 
competence was documented by:  
• successful completion of the certified 
continuing education program in 
pharmaceutical care for patients with diabetes, 
in accordance with the joint recommendations 
of the German Diabetes Society (DDG) and the  
Federal Chamber of Pharmacists (BAK),
35 i.e., 
a 36-hour curriculum, 3-day internship in a 
doctor’s office or clinic specialized in diabetes 
care and final examination. Germany-wide this 
curriculum includes a uniform 8-hour module on 
“Devices and Test Methods“, 
•  or participation in a special intensive seminar 
on diabetes, which was conducted four times in 
2004; certification of completion of the 
DDG/BAK advanced training course was a 
prerequisite, or 
•  active participation in a diabetes-oriented intra- 
or inter-professional quality circle. 
An additional criterion for the pharmacies was the 
existence of a customer data file with at least 50 
type 2 diabetic patients that fulfilled the inclusion 
criteria. 
For eligible patients, the following inclusion criteria 
were defined: 
•  diabetes mellitus type 2 
•  performs self-monitoring of blood glucose 
levels 
•  age at least 18 years 
• speaks  German 
•  capable of interactive cooperation 
•  submits a qualified declaration of consent 
•  willingness to participate in the study 
Further inclusion criteria for the patients were not 
defined in order to depict the day-by-day diabetes 
care as realistically as possible. 
Procedure 
Thirty-two pharmacies took part in the study. Seven 
more pharmacies which were originally registered to 
participate withdrew from the study due to lack of 
time or because of illness of the responsible 
pharmacist. In each pharmacy a special contact 
person for the study center (ABDA) was appointed. 
The study center randomly selected the patients for 
the study out of the pseudonymized pharmacy 
customer data files. Each pharmacy participating in 
the study sent a pseudonymized list extracted from 
the customer file of all type 2 diabetic patients who 
fulfilled the inclusion criteria to the study center. 
Using a random generator, 20 patients were 
selected for each pharmacy to receive an offer to 
participate in the study. Potential replacements for 
the selected patients in case they would not 
participate were also determined.  
In a first step, the selected individuals with type 2 
diabetes were informed in writing about the study 
and were offered the opportunity to participate. In a 
second step they were contacted by telephone. To 
minimize the effort for the participating pharmacies, 
it was decided not to document the patients’ 
reactions to being contacted. 
For each study participant, two individual 
appointments were made in the respective study 
pharmacy: at study entry = t1 and 6 ± 2 weeks post 
= t2. At baseline (t1), a standardized interview was 
first conducted to record basic data. Next, the 
patients measured their blood glucose levels 
independently using their own meters. With the aid 
of a standardized documentation sheet all of the 
individual steps in performing the measurement 
were assessed (checklist). This was followed by 
personalized SMBG exercises and instructions to 
empower the patients to take the measurements 
without making any mistakes. Written instructions 
were provided as a supplement.  
Pharmacies that offer blood glucose testing have a 
separate testing and counseling area, since 
requirements with respect to hygiene and discretion 
must be met. The evaluation of the patients’ self-
monitoring took place in this separate area, as did 
the setting of appointments for the study 
participants, ensuring that the activities of the study 
were clearly separated from the routine operation of 
the pharmacies. 
Sample Size 
The calculation of the sample size was carried out 
with the program nQuery Advisor® 5.0. The basis of 
the calculation was an “SMBG campaign“ that was 
carried out in a community pharmacy in Krefeld, 
Germany, in 2002.
36 Fifty diabetic individuals were 
monitored for potential errors in performing SMBG. 
In 23 (46%) of the individuals, relevant errors were 
determined. This number was used as baseline 
value for the computation of the sample size 
(p=0.54). The objective was defined as a 50% 
increase in the number of patients who perform the 
measurements without making any mistake. The 
McNemar test in the exact version (binomial 
distribution) was used for the calculation. Alpha was 
defined as 0.05 and beta as 0.8. Furthermore, an 
assumed dropout rate was conservatively taken into 
account, as this was observed in another pharmacy-
based project which was a lot more effort- and time-
consuming for the patients (128 of 183 patients 
completed the one-year study).
37 The resulting 
minimal number of cases per subgroup amounted to 
n=69, based on these assumptions. The kind of 
treatment regimen (only insulin, insulin and OAD, 
OAD only) and previous attendance at a training 
session for conducting SMBG were viewed as 
relevant stratifying variables. Thus, the number was 
n=138 per treatment group with the same 
distribution. With respect to stratification dependent 
on the administered treatment, a theoretically 
required total case number N=414 resulted with the 
same subgroup allocation, which, however, was not 
to be assumed initially. Accordingly, this was merely 
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Error Categories 
In principle, every single step of preparing, 
performing, and processing a blood glucose test as 
well as the set-up and condition of the utilized 
technical devices was evaluated as “correct” or 
“incorrect/false”. Individual aspects, which due to 
special device features could not be faulty, e.g. that 
the date and time were already preset or that 
manual coding was not required, were automatically 
evaluated as “correct“. To assess such device-
specific features, the pharmacies participating in the 
study were provided with a detailed device list with 
a presentation of study-specific content as work 
material, in order to standardize the error 
evaluation. 
For the evaluation, an error classification system 
was developed containing a weighting and 
interpretation of the errors and the resulting 
consequences. Errors were classified in the 
categories F1 to F5 (table 1). For the individual 
errors see table 3. 
 
Table 1.Classification of potential errors in conducting blood glucose tests 
 
Error 
Code 
Error Category  Evaluation 
F1 
Errors that make a reading useless (due to the error, it is 
not possible to anticipate whether the measured blood 
glucose level is higher or lower than the true value and 
how great the deviation is). 
If only one of these errors is made, the result cannot 
be interpreted. The test must be repeated (correctly). 
F2  Errors that can lead to a false reading (or a false 
interpretation) in individual cases. 
The significance is dependent on the exact situation 
or the consequence that is drawn. 
F3  Errors that can have a negative effect on compliance. 
These errors have no impact on the measuring 
results, but possibly affect the willingness of the 
patient to perform the self-monitoring  
F4  Errors that can make conducting the test more difficult or 
prevent it entirely (device components). 
Either the handling is unsatisfactory or the 
functionality is impaired. 
F5  Errors which make a consequential action / interpretation 
(by the patient, doctor, or pharmacist) more difficult. 
Readings not available for evaluation over the middle 
term.  
 
Statistical Evaluation 
The primary effect variable was the reduction of the 
number of individuals with type 2 diabetes who 
make errors when self-testing their blood glucose 
levels. Analyses were carried out regardless of the 
kind of error or the error subgroup. The secondary 
effect variable was the reduction of the average 
number of errors per study participant. 
The chi-squared test according to McNemar was 
performed to measure the effect variables if the 
data were dichotomous. With metric data, the t-test 
was performed for paired random samples, since 
due to the selected before-after comparison a 
dependence of the data was given. As a matter of 
principle, an error probability of less than 5% was 
demanded (p<0.05). Testing was always performed 
two sided. 
 
RESULTS  
Patient Characteristics 
Altogether, 478 patients were included in the study. 
This was on average 15 patients per pharmacy. 
Nine patients were excluded from the evaluation, 
because a change to another blood glucose meter 
occurred after the questionnaire data were 
recorded. Four patients did not show up for their t2 
appointment and three were excluded from the 
evaluation due to incomplete data. In total, the data 
of 462 individuals with type 2 diabetes were 
considered in the evaluation. 
The percentage of women (54%) among the 
participants was higher than the percentage of men. 
The average age of the participants was 67 years. 
(SD=10.3; range=27-89). There were no sex-
specific differences with regard to age, diabetes 
duration, participation in a disease management 
program (DMP) and how long the patient had been 
performing SMBG. However, it was significantly 
more frequent that female patients had less school 
education than the male patients (p<0.05). The 
average diabetes duration was 13.1 years (SD=9.4; 
range=0-46) and the average duration of performing 
SMBG was 7 years (SD=6.2; range=0-43). 37% of 
the patients (n=171) stated at study begin that they 
were taking or had taken part in a DMP “type 2 
diabetes mellitus”. Additional socio-demographical 
data are presented in table 2. 
Table 2. Description of the study population (N=462) 
Age (years)  Number  % 
Under 50  28  6.1 % 
50 – 59  73  15.8 % 
60 – 69  159  34.4 % 
70 – 75  108  23.4 % 
76 and older  94  20.3 % 
Years of school 
Under 8  9  2.0 % 
8 - 9  298  64.5 % 
10 – 11  100  21.6 % 
12 – 13  43  9.3 % 
More than 13  5  1.1 % 
No data available  7  1.5 % 
Duration of diabetes (years) 
1 or less  27  5.8 % 
2 – 5   87  18.8 % 
6 – 10   110  23.8 % 
11 – 15   83  18.0 % 
16 or more  152  33.0 % 
No data available  3  0.6 % 
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Drug Therapy 
Of the 462 study participants, about 70% (n=325) 
stated that they administered insulin. Of these, 193 
study participants stated that they use insulin only, 
and the remaining 132 took an OAD additionally 
(figure 1). Of the 325 insulin users, 190 (58%) 
stated that they adjusted their dosage depending on 
the individual blood glucose level that was 
measured. 
3%
27%
40%
1%
29%
Neither insulin nor oral antidiabetic drugs Only oral antidiabetic drugs
Only Insulin Insulin pump
Insulin & oral antidiabetic drugs
 
Figure 1: Therapy scheme of study population (n=460; no 
data available for two patients) 
336 study participants (73%) stated that they 
measured their blood glucose at least once daily or 
more often. 30% stated that they measured their 
blood glucose four times a day or more often 
(n=139), just as many measured between two or 
three times a day. Only 11% measured once a 
week or less often. Over 61% of the diabetic 
patients (n=283) had already attended one or two 
instruction sessions on how to perform SMBG, 17% 
had already attended three or four sessions and 8% 
even five or more. More than 13% (n=61) stated 
they had never received an introduction into SMBG. 
The study participants had most often 
demonstrations (63%) and oral instructions (58%)  
274 patients stated that they were educated in 
managing their diabetes in a doctor’s office, 161 in a 
hospital and 86 in a pharmacy. Other individual 
patients stated that they received diabetes 
management education from acquaintances, 
medical insurance companies or nursing services.  
Error Description 
Pressing the finger tip during blood extraction was 
the error most frequently documented. This error 
was observed with 216 patients (49%). The second 
most frequent error occurred during adjustment of 
the settings (date, time) and was observed with 209 
patients. This error has no influence on the integrity 
of the reading, but it can make an interpretation of 
the measurements more difficult later. All other 
errors corresponding to their frequency observed at 
t1 are presented in table 3. 
 
Table 3. Frequency of the occurrence of individual errors in N = 462 patients at t1 and t2, respectively, and the 
correlation to the different error classes  
t1 T2 
Possible sources of error  Error 
class  Number 
[n] 
Percent 
[%] 
Number 
[n] 
Percent 
[%] 
Squeezing out the blood   F1  216  46.8  77  16.7 
Settings (date, time)  F5  209  45.2  65  14.1 
Sideways pricking of the finger pad  F3  157  34.0  36  7.8 
Hand-washing F1  99  21.4  20  4.3 
Inserting / changing the lancet (skill)  F3  83  18.0  22  4.8 
Stimulating circulation (if needed)  F3  81  17.5  13  2.8 
Drying the hands  F1  71  15.4  6  1.3 
Adjusting the prick depth  F3  63  13.6  8  1.7 
Closing the test strip container after taking one out  F2  59  12.8  15  3.3 
Documentation / saving the result  F5  55  11.9  11  2.4 
If disinfected, was the skin dry?  F1  52  11.3  10  2.2 
Checking the coding  F1  41  8.9  8  1.7 
Cleanliness of device and measuring cell   F2  37  8.0  14  3.0 
Sufficiently large drop of blood extracted   F2  26  5.6  6  1.3 
Applying the blood sample / absorption of the test field  F2  25  5.4  6  1.3 
Quantity of the applied blood  F2  25  5.4  6  1.3 
Changing the coding (if required)  F1  21  4.6  4  0.9 
Loading the lancet  F4  18  3.9  3  0.7 
Expiration date of the test strips  F1  15  3.3  5  1.1 
Storage conditions of the test strips  F1  14  3.0  0  0 
Inserting the test strip / inserting the disk  F4  14  3.0  5  1.1 
Check with the glucose control solution  F1  13  2.8  3  0.7 
Condition of the battery  F4  12  2.5  8  1.7 
Basic handling of the measuring device  F4  4  0.9  0  0 
Choice of the desired unit (mg/dL, mmol/L)  F2  2  0.4  2  0.4 
Use of correct test strips  F1  0  0  0  0 
Apart from the errors that were listed last (irrelevant 
due to the observed frequency), all other errors 
could be reduced significantly and on a relevant 
scale for the day-to-day self-monitoring, within the 
scope of this study (table 3).  
Measurement Quality  
At study entry (t1), 79 of 462 patients (17%) carried 
out the measurement without making any mistakes. 
At t2 the proportion was 272 or 59% of the study 
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faulty measurements could be reduced by more 
than half, from 83% at the beginning to 41% at t2. 
Moreover, the average number of errors per patient 
could be reduced from 3.1 to 0.8 (p<0.001).  
Table 4 shows the number of patients with faulty 
measurements in total as well as separately for the 
individual error categories. 
 
The greatest improvement was in error group F3 
(errors that can have a negative impact on 
compliance) with a reduction of around 74%. Since 
this error group contains parameters that directly 
influence the amount of pain felt, this observation is 
plausible. The errors in category F1 are of special 
significance because they can render a reading 
useless, making it impossible to anticipate whether 
the measured blood glucose level is higher or lower 
than the true value and how great the deviation is. 
These errors could be reduced from initially 283 
patients with measurement errors to 111 patients 
with such mistakes. This corresponds to a reduction 
of 60%. All achieved differences between t1 and t2 
were statistically significant. 
Subgroup Analyses 
Subgroup analyses were performed depending on 
the different drug therapy options, i.e. only insulin, 
insulin and OAD, and OAD only. 
The average number of errors of the patients who 
were treated solely with OAD dropped over the 
period of the study from 4.1 errors to 1 error per 
patient. In the group of patients that in addition to 
OAD also received insulin, the average number of 
errors dropped from 2.7 to 0.7. In the participants 
who received insulin therapy exclusively, the initial 
number of errors dropped from 2.6 to 0.7. All of the 
improvements were statistically significant.  
In addition, due to the special relevance, the 
subgroup of patients with insulin therapy who adjust 
their insulin dose on the basis of their self-measured 
blood glucose readings was analyzed (n=190). In 
total at t1, 142 of these 190 study participants (75%) 
made at least one error while measuring. Errors 
from category F1, which make a measurement 
useless, were documented for 100 of these 190 
diabetic patients (53%). The number of patients who 
at the end of the study could not perform the 
measurements without making mistakes was 
reduced to 66 (35%). In relation to error category F1 
at t2, 41 patients (22%) still made such errors. 
These changes were also statistically significant. 
 
DISCUSSION 
This study shows that the majority of individuals 
with type 2 diabetes (83%) make at least one 
mistake in carrying out the measurement of blood 
glucose levels with their own device. The study 
revealed two kinds of errors that were quite 
frequent: errors that falsify the measurement 
reading as well as errors that can have a negative 
effect on patient compliance. In the reference 
literature there is a consensus that individuals with 
diabetes make numerous mistakes in the self-
monitoring of their blood glucose levels and that 
remedial training sessions are required.
22-30,33,34,38,39 
But there is little data on how much impact to expect 
from these remedial training sessions for type 2 
diabetic patients. One problem is that there is no 
standard method for remedying the errors, so that 
the kind of error assessment is variable at the time 
of our study. A validated documentation sheet was 
not available. The documentation sheets used in 
various studies
22 are designed to record 13 to 45 
sources of error.
31 Thus, no comparability exists 
among the various studies. The main difference in 
the evaluations consisted in whether the 
components of the SMBG were summarized or 
recorded in a very detailed way. Common to all of 
them, however, is that it could be shown in principle 
that diabetes management education sessions 
instructing how to carry out blood glucose self-
testing are both necessary and effective, even if no 
general statement could be made about the extent 
of the success.
25,29,30  
The kinds of mistakes observed in the studies, 
however, were very similar. In other studies, too, the 
main mistakes were in cleaning of the hands, 
making adjustments to the settings of the meter and 
problems with coding.
23,30,31 
The study presented here was able to show that a 
one-time, standardized intervention in community 
pharmacies specialized in diabetes care is able to 
more than triple the number of patients who carried 
out the self-monitoring without making any errors: 
initially 17% compared to 59% at the end of the 
study. However, a selection bias in the patient 
population of the study cannot be fully excluded, 
since such offers are probably accepted more 
Table 4. Number of errors of the patients (N = 462) in blood glucose self-testing at t1 and t2, respectively, in 
total and according to the different error categories. 
Patients at t1 
with > 1 errors 
Patients at t2 
with > 1 errors  Error category 
[n] [%] 
Average 
number of 
errors  [n] [%] 
Average 
number of 
errors 
p-value 
(t-test) 
Total 383  82.9  3.1  190  41.1  0.8  <  0.001 
F1 283  61.3  1.5  111  24.0  0.4  <  0.001 
F2 123  26.6  0.8  42  9.1  0.2  <  0.001 
F3 240  52.0  0.8  62  13.4  0.2  <  0.001 
F4 42  9.1  0.1  16  3.5  0.0  =  0.002 
F5 225  48.7  0.6  74  16.0  0.2  <  0.001 
F1 or F2  310  67.1  1.5  126  27.3  0.4  < 0.001 Müller U, Hämmerlein A, Casper A, Schulz M. Community Pharmacy-Based Intervention to Improve Self-Monitoring of 
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frequently by motivated patients rather than by 
unmotivated patients.  
Altogether, the pharmacy setting is suited for 
carrying out such evaluations along with giving 
corresponding instructions on how to correctly 
perform SMBG. Such an intervention comprised 
verbal instructions as well as practical exercises 
and took on average about 20 to 30 minutes, 
including the study documentation.  
One reservation regarding our study is that any 
SMBG training sessions that may have taken place 
outside the pharmacy in the period of six weeks 
between t1 and t2 were not recorded, but this would 
have only distorted the result false-positively. 
However, this error is probably negligible with 
respect to the size of the effect found. 
A further limitation of the study is due to the fact that 
the chosen design did not allow for checking the 
accuracy of the blood glucose readings, since the 
required extraction of venous blood for a 
comparative measurement is not possible in the 
setting of a community pharmacy in Germany. 
Thus, no assertions can be made about the extent 
the readings deviated from a comparative lab 
control reading due to the observed errors.  
Whether the positive effect will be sustained past 
the trial period cannot be answered with the present 
study. Presumably, it would be necessary to repeat 
the diabetes management education sessions to 
ensure the most accurate measurements possible 
over the long term.  
Another topic that must be discussed is that the 
results show that such one-time interventions are 
not sufficient for all patients to learn how to perform 
error-free measurements. Additional follow-up 
instructions and exercises would probably increase 
the number of type 2 diabetic patients who could 
monitor their blood glucose levels without making 
any mistakes. However, even then, probably not all 
patients would be capable of performing error-free 
measurements. For this group of individuals it might 
be a good option to integrate another person, e.g. 
the spouse or partner, into the measuring of the 
blood glucose levels. 
 
CONCLUSIONS 
Through a one-time intervention as described here, 
the number of patients making mistakes in SMBG 
was reduced by half over a period of six weeks. In 
view of this background, the results of the present 
study are practice relevant. A concept like in figure 
2 could possibly show how an evaluation of SMBG 
in pharmacies can be integrated into the given care 
process of individuals with type 2 diabetes. 
Accordingly, such an evaluation could take place 
following the physician’s diabetes management 
education program. Patients who measure without 
making any mistakes should repeat this process 
once a year or when they switch to another blood 
glucose meter. Patients who make mistakes in 
carrying out their SMBG should receive instruction 
in the pharmacy once. If this does not lead to error-
free self-testing, remedial training should be given 
by the physician and his diabetes team.  
Error-free SMBG?
YES NO
No intervention Intervention as described in 
this study
Evaluation of SMBG
Error-free SMBG? NO YES 12 months later or 
with new device
Evaluation of SMBG in the pharmacy
Patient education conducted by physician and 
diabetes team
Error-free SMBG?
YES NO
No intervention Intervention as described in 
this study
Evaluation of SMBG
Error-free SMBG? NO YES 12 months later or 
with new device
Evaluation of SMBG in the pharmacy
Patient education conducted by physician and 
diabetes team
 
Figure 2. Suggestion for an implementation scheme to integrate the evaluation of SMBG in pharmacies in the healthcare 
process of individuals with type 2 diabetes 
 
In community pharmacies this approach should be 
integrated into the existing pharmaceutical care 
concepts for patients with diabetes, which in our 
case were worked out in detail by a commission of 
the German Diabetes Society (DDG) and the 
Federal Chamber of Pharmacists (BAK) and 
published under the title “Integration of Pharmacists 
into Diabetic Care“.
35,40,41 The prerequisite for 
providing such concerted and qualified care would 
include the following elements: (i) DDG/BAK-Müller U, Hämmerlein A, Casper A, Schulz M. Community Pharmacy-Based Intervention to Improve Self-Monitoring of 
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certified advanced training diabetes program, which 
until now more than 5,500 pharmacists across 
Germany have completed. (ii) working in 
compliance with the consensus agreements 
regarding the competences of the different 
healthcare professions,
35 and (iii) working with 
quality assurance instruments such as Standard 
Operating Procedures and checklists, e.g. with 
instructions for SMBG.
42 Through regular monitoring 
of how well the patient performs the measurements, 
the patient’s skill and security in dealing with the 
self-test can be increased. Moreover, through 
device function checks, the reliability of the blood 
glucose meter can be ensured. The study also 
showed a high number of patients complying with 
special instructions about how to extract capillary 
blood less painfully, since they benefit directly.  
It should be investigated whether such instruction 
sessions in the pharmacy can reduce superfluous 
self-testing to a certain extent and thus make a 
contribution to a more efficient use of blood glucose 
test strips. 
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